一图看懂翰森制药(3692.HK)IPO
中国创新药企业翰森制药(3692.HK)本周发布公告,招股章程所述的超额配股权获联席全球协调人(代表国际包销商)悉数行使,涉及合共8269.2万股发售股份,占根据全球发售初步可供认购发售股份总数的15%,以补足国际发售的超额分配。超额配发股份将由公司按每股股份14.26港元(即全球发售项下的每股发售股份发售价)配发及发行。
翰森制药是为数不多的以研发为驱动的中国制药公司之一,在中国一些规模最大、发展最快而具有重大未满足临床需求的治疗领域中拥有领先地位。翰森在中枢神经系统疾病、抗肿瘤、抗感染、及糖尿病方面拥有广泛、多元化及领先的药物组合,还专注于消化道及心血管治疗领域。
回顾挂牌首日,翰森制药大幅高开超过14%,随后冲高,盘中一度涨幅超47%。截至2019年7月12日收盘,翰森制药相对发行价上涨67.95%,报23.95港元,最新总市值1386亿港元,成为新港股创新药企龙头。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.